Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.45 |
---|---|
High | 2.47 |
Low | 2.30 |
Bid | 2.37 |
Offer | 2.38 |
Previous close | 2.41 |
Average volume | 2.08m |
---|---|
Shares outstanding | 82.55m |
Free float | 82.28m |
P/E (TTM) | -- |
Market cap | 195.64m USD |
EPS (TTM) | -2.56 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Third Quarter 2024 Results and Business Updates
- Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
- Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
- Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
- Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
More ▼